-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Dual Exhibitions on One Stage, Full-Chain Collaboration | Keyuan Pharmaceutical, together with its subsidiary Linuo Pharmaceutical, jointly showcased at the Shanghai International Pharmaceutical Dual Exhibitions!
Publish Time:
2026-05-13
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediates, Packaging, and Equipment Fair (API China) opened simultaneously at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing synergistic raw material–formulation integration, end-to-end product displays, and brand resonance. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore new industry trends, expand avenues for collaboration, and build a new ecosystem for the pharmaceutical and healthcare sectors.
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediates, Packaging, and Equipment Fair (API China) opened simultaneously at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing synergistic raw material–formulation integration, end-to-end product displays, and brand resonance. The company highlighted its robust capabilities in innovative R&D, intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore new industry trends, expand cooperation opportunities, and build a new ecosystem for the pharmaceutical and healthcare sectors.
Gathering Momentum in Shanghai, Walking Forward Together
The dual exhibitions illuminate a new chapter, fostering collaboration for mutual benefit.
This year’s dual exhibitions are being held jointly, with a combined exhibition space exceeding 170,000 square meters. They bring together nearly 4,000 high-quality exhibitors and 200,000 professional visitors, spanning the entire pharmaceutical value chain—from active pharmaceutical ingredients and finished dosage forms to packaging materials, equipment, and distribution. As China’s largest, most prestigious, and most influential annual flagship event in the pharmaceutical industry, it provides an authoritative and highly efficient platform for companies to engage in technological exchange, showcase their brands, and facilitate business matchmaking.
At the exhibition booth, Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President, led the company’s core team to the front lines, engaging in in-depth exchanges and precise negotiations with new and longstanding partners from across the country. They carefully listened to market needs, analyzed industry trends, and jointly discussed strategies for channel expansion and industrial collaboration, thereby fully demonstrating the company’s customer‑centric, market‑driven development philosophy and its unwavering commitment to deepening its presence in the pharmaceutical sector.
Parent Company Leads the Way, Building a Solid Foundation with Robust Capabilities
Integrated planning strengthens the foundation, while digital intelligence empowers enhanced quality and efficiency.
Keyuan Pharmaceutical is anchored by an integrated API–formulation strategy, focusing on its core therapeutic areas of diabetes, anesthesia, cardiovascular health, and psychiatry. At the API China exhibition, the company showcases high‑quality chemical APIs, specialty intermediates, and cutting‑edge achievements in green intelligent manufacturing. Leveraging AI‑driven, all‑scenario applications, data management, and smart manufacturing as strategic pillars, Keyuan is comprehensively advancing the digital and intelligent transformation of its production facilities. The company has established dual R&D centers in Beijing and Jinan, supported by six robust technology platforms, and continues to drive breakthroughs in key technologies such as enzyme catalysis, continuous flow processes, and chiral catalysis. With a commitment to reliable supply, stringent quality control, and world‑class production capabilities, Keyuan has garnered significant attention from global buyers and strategic partners.
In the first quarter of 2026, the company reported operating revenue of RMB 161 million, up 45.05% year over year, and net profit attributable to shareholders of RMB 30.07 million, up 30.27% year over year. Both operating performance and earnings quality improved in tandem, laying a solid foundation for the Group’s high-quality development.
Subsidiary Revitalized, New Products Shine
A full‑chain matrix illuminates the City of Shanghai, while匠心‑crafted new products usher in a new journey.
Linuo Pharmaceutical made a high‑profile appearance at the national pharmaceutical trade fair, leveraging its full‑chain synergies with Keyuan Pharmaceutical and harnessing capital to build a comprehensive product portfolio spanning all dosage forms—including injectables, oral solutions, drops, liniments, pastes, and sprays. Guided by pressing market needs, the company showcased premium formulations across diverse therapeutic areas such as chronic disease management, anti‑infection, and anti‑inflammatory treatments.
On the eve of the conference, at the client appreciation gala, Linuo Pharmaceutical solemnly held a launch ceremony for six major new products, officially introducing sodium alendronate tablets, levocetirizine dihydrochloride tablets, vancomycin hydrochloride for injection, isavuconazole sulfate for injection, betahistine hydrochloride tablets, and diphenhydramine hydrochloride tablets. The event featured a comprehensive overview of each product’s clinical value, market prospects, and channel strategies.
Raw Material and Formulation Synergy: Steady Progress for Lasting Success
Dual-core synergy builds end-to-end competitiveness, demonstrating resilience in navigating market cycles.
In recent years, Keyuan Pharmaceutical and Linuo Pharmaceutical have adhered to an integrated parent–subsidiary model driven by dual core capabilities and coordinated development across the entire value chain. Guided by five foundational strategies—AI‑powered all‑scenario applications, technological innovation, internet‑based thinking, data management, and investment & financing—they have established world‑class smart manufacturing facilities for APIs, injectables, solid dosage forms, and other product lines. This has enabled deep, end‑to‑end integration between API and formulation production, as well as between excipients and finished products, ensuring rigorous quality control at the source, reducing costs while boosting efficiency, and securing supply. As a result, they have built robust, full‑chain core competencies spanning R&D innovation, lean manufacturing, and market promotion, sustaining steady growth and demonstrating strong resilience in navigating industry cycles.
The brand sets sail, with a promising future.
Dual Exhibitions Empower and Showcase Excellence, Joining Forces to Build a Healthy Future
The dual exhibitions, held under one roof, underscore the strength of our brand; seamless collaboration across the entire value chain ushers in a new chapter of growth. This joint appearance at the Shanghai International Pharmaceutical Exhibition is not only a comprehensive showcase of Koyuan Pharmaceutical Group’s achievements in building an end-to-end industrial ecosystem, pursuing integrated development, and implementing brand‑driven operations, but also a pivotal step in the Group’s strategic commitment to deepening its presence in the domestic market while embracing global opportunities, thereby actively contributing to the broader drive for high‑quality development in the pharmaceutical industry.
Looking ahead, Keyuan Pharmaceutical will continue to join forces with Luno Pharmaceutical, staying true to its original mission of caring for life and health and safeguarding a better future. Guided by innovation as its soul, intelligent manufacturing as its foundation, and collaboration as its wings, the company will steadily strengthen R&D investment, upgrade smart manufacturing, optimize its product portfolio, and deepen its global footprint. Working hand in hand with partners at home and abroad, Keyuan Pharmaceutical will contribute even greater strength to advancing China’s pharmaceutical industry toward high-end, intelligent, and international standards, and to building a Healthy China and a strong national brand.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline